patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_568413 | REC_0010201 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5 | 79 | female | 2 | 13 | 4.1 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:35:59.395783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548580 | REC_0010202 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 11.9 | 51 | male | 0 | 12 | 5.2 | 1 | entrectinib 600 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:59.396032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879452 | REC_0010203 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 7.4 | 73 | female | 1 | 7 | 3.8 | 3 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:35:59.396349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546761 | REC_0010204 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.7 | 67 | female | 1 | 49 | 5.1 | 9 | carboplatin + paclitaxel + pembrolizumab | 15.9 | true | MSS | 2026-03-15T05:35:59.396601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533827 | REC_0010205 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.9 | 63 | female | 1 | 14 | 6.2 | 5 | entrectinib 600 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:35:59.396867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802354 | REC_0010206 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 9.7 | 73 | female | 2 | 16 | 2.1 | 5 | osimertinib 80 mg daily | 6.1 | false | MSS | 2026-03-15T05:35:59.397236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856053 | REC_0010207 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.7 | 70 | female | 2 | 22 | 8.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.8 | false | MSS | 2026-03-15T05:35:59.397497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439016 | REC_0010208 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 22 | 7.5 | 69 | female | 1 | 18 | 4.9 | 0 | alectinib 600 mg BID | 26.7 | false | MSS | 2026-03-15T05:35:59.397753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141951 | REC_0010209 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 13.6 | 81 | female | 1 | 9 | 4.6 | 5 | osimertinib 80 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:59.398015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122614 | REC_0010210 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 9.7 | 57 | female | 1 | 15 | 4.3 | 6 | sotorasib 960 mg daily | 14.2 | true | MSS | 2026-03-15T05:35:59.398264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234064 | REC_0010211 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.8 | 68 | female | 0 | 18 | 5.4 | 5 | sotorasib 960 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:59.398497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524744 | REC_0010212 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 9.3 | 77 | female | 1 | 10 | 5.6 | 5 | osimertinib 80 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:59.398746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207918 | REC_0010213 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.6 | 71 | female | 2 | 56 | 4.3 | 4 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:59.399013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440299 | REC_0010214 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 9 | 75 | female | 0 | 46 | 6.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:35:59.399314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535079 | REC_0010215 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 6.3 | 75 | female | 1 | 22 | 6.3 | 2 | entrectinib 600 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:59.399610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838612 | REC_0010216 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 16.3 | 67 | male | 0 | 22 | 5.7 | 1 | sotorasib 960 mg daily | 14.5 | false | MSI-H | 2026-03-15T05:35:59.399896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910631 | REC_0010217 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 14.2 | 70 | female | 0 | 10 | 3.9 | 1 | alectinib 600 mg BID | 28.7 | false | MSI-H | 2026-03-15T05:35:59.400226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344229 | REC_0010218 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 14.7 | 40 | female | 0 | 13 | 4 | 7 | alectinib 600 mg BID | 13.6 | false | MSS | 2026-03-15T05:35:59.400540+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355067 | REC_0010219 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 11.5 | 57 | male | 0 | 10 | 6 | 6 | sotorasib 960 mg daily | 17.4 | false | MSI-H | 2026-03-15T05:35:59.400982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827709 | REC_0010220 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 9.8 | 66 | female | 1 | 7 | 4.5 | 5 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:59.401316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599576 | REC_0010221 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 3.6 | 64 | female | 1 | 52 | 4.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.1 | false | MSS | 2026-03-15T05:35:59.401607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815814 | REC_0010222 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 6.9 | 70 | female | 2 | 19 | 6 | 9 | entrectinib 600 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:59.401864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241769 | REC_0010223 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 9.4 | 68 | female | 0 | 20 | 5.3 | 7 | alectinib 600 mg BID | 15.8 | true | MSS | 2026-03-15T05:35:59.402133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144438 | REC_0010224 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 9.5 | 58 | male | 0 | 16 | 5.2 | 2 | entrectinib 600 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:59.402404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594120 | REC_0010225 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 13 | 55 | female | 0 | 22 | 6.3 | 2 | entrectinib 600 mg daily | 11 | false | MSS | 2026-03-15T05:35:59.402693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199451 | REC_0010226 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 3.1 | 64 | male | 1 | 17 | 3.8 | 6 | pembrolizumab 200 mg q3w | 12.7 | true | MSS | 2026-03-15T05:35:59.402972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146969 | REC_0010227 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 16.8 | 72 | female | 2 | 14 | 2.6 | 1 | alectinib 600 mg BID | 17.3 | true | MSI-H | 2026-03-15T05:35:59.403236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197159 | REC_0010228 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 15.8 | 67 | female | 0 | 2 | 4.8 | 2 | sotorasib 960 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:59.403509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755824 | REC_0010229 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.6 | 68 | female | 0 | 62 | 3.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.5 | false | MSS | 2026-03-15T05:35:59.403781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733159 | REC_0010230 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 6.4 | 61 | male | 0 | 9 | 4.9 | 1 | sotorasib 960 mg daily | 30.6 | true | MSS | 2026-03-15T05:35:59.404173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203695 | REC_0010231 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 5.1 | 64 | male | 1 | 8 | 6.3 | 2 | pembrolizumab 200 mg q3w | 5.8 | false | MSS | 2026-03-15T05:35:59.404542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356648 | REC_0010232 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 7.8 | 66 | female | 0 | 8 | 4 | 5 | alectinib 600 mg BID | 8.9 | true | MSS | 2026-03-15T05:35:59.404985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_292020 | REC_0010233 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5.8 | 74 | female | 2 | 41 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.4 | true | MSS | 2026-03-15T05:35:59.405321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826205 | REC_0010234 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 17.9 | 60 | female | 0 | 11 | 4.8 | 1 | alectinib 600 mg BID | 9.8 | false | MSS | 2026-03-15T05:35:59.405630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691260 | REC_0010235 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 14.7 | 63 | female | 0 | 4 | 6.1 | 1 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:59.405923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495619 | REC_0010236 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 6.3 | 64 | female | 0 | 24 | 5 | 4 | entrectinib 600 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:59.406238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626665 | REC_0010237 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.6 | 64 | female | 1 | 2 | 6.3 | 5 | osimertinib 80 mg daily | 11.3 | true | MSS | 2026-03-15T05:35:59.406592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575887 | REC_0010238 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 4.3 | 63 | male | 0 | 21 | 5.3 | 7 | alectinib 600 mg BID | 10.8 | true | MSS | 2026-03-15T05:35:59.407327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709030 | REC_0010239 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.8 | 55 | male | 0 | 13 | 5.5 | 5 | osimertinib 80 mg daily | 18 | false | MSS | 2026-03-15T05:35:59.407689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256031 | REC_0010240 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 8.6 | 69 | female | 1 | 34 | 5.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:35:59.408035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984353 | REC_0010241 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 15.2 | 63 | male | 0 | 13 | 6.7 | 6 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:59.408471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700543 | REC_0010242 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13.8 | 58 | female | 0 | 15 | 3.5 | 1 | sotorasib 960 mg daily | 18.8 | false | MSS | 2026-03-15T05:35:59.408834+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888313 | REC_0010243 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 15.8 | 66 | female | 1 | 21 | 5.7 | 6 | osimertinib 80 mg daily | 13.5 | true | MSS | 2026-03-15T05:35:59.409142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997558 | REC_0010244 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 9.5 | 63 | female | 1 | 21 | 5.7 | 5 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:59.409418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390698 | REC_0010245 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.5 | 75 | female | 2 | 19 | 4.8 | 5 | osimertinib 80 mg daily | 17.6 | true | MSI-H | 2026-03-15T05:35:59.409920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528337 | REC_0010246 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.3 | 76 | female | 3 | 11 | 4.7 | 4 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:59.410331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476917 | REC_0010247 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.2 | 74 | male | 1 | 11 | 6 | 7 | alectinib 600 mg BID | 11.5 | false | MSI-H | 2026-03-15T05:35:59.410694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720169 | REC_0010248 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.1 | 65 | male | 0 | 14 | 6.6 | 7 | pembrolizumab 200 mg q3w | 12.4 | false | MSS | 2026-03-15T05:35:59.411058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342977 | REC_0010249 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 15 | 9.5 | 71 | female | 1 | 16 | 5.7 | 2 | sotorasib 960 mg daily | 9 | false | MSS | 2026-03-15T05:35:59.411412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578527 | REC_0010250 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 3.5 | 64 | male | 1 | 51 | 5.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 8 | false | MSS | 2026-03-15T05:35:59.411741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847418 | REC_0010251 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.9 | 74 | female | 2 | 62 | 6.5 | 9 | carboplatin + paclitaxel + pembrolizumab | 8 | true | MSS | 2026-03-15T05:35:59.412022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495376 | REC_0010252 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 19.4 | 64 | male | 1 | 20 | 5 | 7 | alectinib 600 mg BID | 4.9 | true | MSI-H | 2026-03-15T05:35:59.412577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733291 | REC_0010253 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 14.8 | 73 | female | 2 | 12 | 5.3 | 2 | entrectinib 600 mg daily | 22.2 | false | MSI-H | 2026-03-15T05:35:59.412889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350507 | REC_0010254 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 5.5 | 61 | male | 0 | 23 | 5.9 | 6 | pembrolizumab 200 mg q3w | 13.6 | false | MSS | 2026-03-15T05:35:59.413153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356174 | REC_0010255 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 8.5 | 77 | male | 1 | 11 | 5.2 | 5 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:59.413420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808983 | REC_0010256 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 23 | 4.2 | 76 | female | 1 | 51 | 8.2 | 0 | pembrolizumab 200 mg q3w | 34.8 | false | MSS | 2026-03-15T05:35:59.413669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513187 | REC_0010257 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.2 | 69 | female | 0 | 42 | 6.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.9 | true | MSS | 2026-03-15T05:35:59.413910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213246 | REC_0010258 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 6.6 | 60 | female | 1 | 16 | 4.1 | 5 | entrectinib 600 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:59.414320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432650 | REC_0010259 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 14.8 | 72 | female | 2 | 25 | 6.3 | 1 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:59.414593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291953 | REC_0010260 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 14.1 | 83 | female | 1 | 17 | 4 | 3 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:59.414855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712007 | REC_0010261 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 5.3 | 73 | female | 1 | 26 | 6 | 8 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:35:59.415109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390190 | REC_0010262 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 19 | 65 | female | 0 | 12 | 8.4 | 5 | sotorasib 960 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:59.415383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154920 | REC_0010263 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 7.6 | 61 | male | 1 | 48 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.4 | true | MSS | 2026-03-15T05:35:59.415637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304506 | REC_0010264 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.3 | 39 | female | 0 | 21 | 5 | 5 | osimertinib 80 mg daily | 9.5 | true | MSI-H | 2026-03-15T05:35:59.415891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126103 | REC_0010265 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 8.4 | 52 | male | 0 | 19 | 3.1 | 6 | pembrolizumab 200 mg q3w | 5.8 | true | MSS | 2026-03-15T05:35:59.416226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448196 | REC_0010266 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.6 | 60 | male | 1 | 17 | 7.2 | 5 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:59.416522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181088 | REC_0010267 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.1 | 78 | female | 2 | 35 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.6 | false | MSS | 2026-03-15T05:35:59.416803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535137 | REC_0010268 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 15.7 | 74 | female | 2 | 13 | 6.7 | 4 | osimertinib 80 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:59.417121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954278 | REC_0010269 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 8.7 | 58 | male | 0 | 13 | 7.6 | 1 | sotorasib 960 mg daily | 16 | false | MSS | 2026-03-15T05:35:59.417431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490301 | REC_0010270 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 15.4 | 62 | male | 1 | 16 | 5 | 1 | osimertinib 80 mg daily | 17 | true | MSS | 2026-03-15T05:35:59.417778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433225 | REC_0010271 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 13.2 | 63 | female | 0 | 13 | 6.9 | 6 | alectinib 600 mg BID | 5.1 | true | MSS | 2026-03-15T05:35:59.418296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782334 | REC_0010272 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 4.8 | 68 | female | 1 | 11 | 6.7 | 2 | pembrolizumab 200 mg q3w | 24.7 | false | MSS | 2026-03-15T05:35:59.418639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571176 | REC_0010273 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 7.8 | 67 | female | 1 | 22 | 5.8 | 6 | entrectinib 600 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:59.418938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371448 | REC_0010274 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 4.1 | 51 | male | 0 | 39 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.1 | false | MSS | 2026-03-15T05:35:59.419235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417860 | REC_0010275 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.9 | 49 | female | 0 | 32 | 6.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.6 | true | MSS | 2026-03-15T05:35:59.419494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556706 | REC_0010276 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.7 | 70 | female | 1 | 37 | 8 | 9 | carboplatin + paclitaxel + pembrolizumab | 8.6 | true | MSS | 2026-03-15T05:35:59.419738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269862 | REC_0010277 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 18.1 | 75 | female | 1 | 24 | 6.2 | 1 | entrectinib 600 mg daily | 17 | false | MSI-H | 2026-03-15T05:35:59.419990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949458 | REC_0010278 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 9.3 | 61 | male | 1 | 14 | 6.4 | 5 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:59.420289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862544 | REC_0010279 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 10 | 62 | male | 1 | 16 | 6.2 | 2 | osimertinib 80 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:35:59.420535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125854 | REC_0010280 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.5 | 65 | male | 1 | 11 | 5.6 | 4 | sotorasib 960 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:35:59.420771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342318 | REC_0010281 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 8.9 | 67 | female | 1 | 0 | 5.6 | 7 | alectinib 600 mg BID | 10.3 | true | MSS | 2026-03-15T05:35:59.421008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578590 | REC_0010282 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.6 | 64 | female | 1 | 47 | 5.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:59.421240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828064 | REC_0010283 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 10.8 | 38 | female | 0 | 7 | 6.2 | 4 | sotorasib 960 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:35:59.421476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529117 | REC_0010284 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6 | 80 | male | 2 | 29 | 5.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.3 | true | MSS | 2026-03-15T05:35:59.421808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346992 | REC_0010285 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.4 | 70 | female | 1 | 3 | 6.2 | 8 | alectinib 600 mg BID | 12.4 | false | MSI-H | 2026-03-15T05:35:59.422047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629277 | REC_0010286 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 6.9 | 60 | female | 0 | 3 | 5.3 | 1 | osimertinib 80 mg daily | 17.6 | false | MSS | 2026-03-15T05:35:59.422284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669936 | REC_0010287 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.8 | 76 | male | 0 | 26 | 4.5 | 5 | osimertinib 80 mg daily | 4.6 | true | MSS | 2026-03-15T05:35:59.422519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331387 | REC_0010288 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 15.5 | 60 | male | 1 | 19 | 3.8 | 1 | osimertinib 80 mg daily | 19.3 | false | MSI-H | 2026-03-15T05:35:59.422754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624670 | REC_0010289 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 5 | 61 | female | 1 | 11 | 7.2 | 2 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:59.422985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258564 | REC_0010290 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 13.8 | 57 | male | 0 | 18 | 6.3 | 5 | osimertinib 80 mg daily | 4.8 | false | MSI-H | 2026-03-15T05:35:59.423217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419675 | REC_0010291 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 15.3 | 57 | female | 1 | 15 | 7.7 | 1 | sotorasib 960 mg daily | 19.5 | false | MSI-H | 2026-03-15T05:35:59.423448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_668210 | REC_0010292 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 18.9 | 77 | female | 1 | 16 | 6.3 | 0 | osimertinib 80 mg daily | 20.5 | true | MSS | 2026-03-15T05:35:59.423679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351570 | REC_0010293 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 7.9 | 67 | female | 0 | 9 | 6.6 | 6 | osimertinib 80 mg daily | 5.8 | false | MSS | 2026-03-15T05:35:59.423905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706004 | REC_0010294 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 5.4 | 63 | male | 1 | 19 | 5.8 | 1 | entrectinib 600 mg daily | 17.2 | true | MSS | 2026-03-15T05:35:59.424173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183786 | REC_0010295 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 9.5 | 66 | female | 0 | 26 | 6 | 1 | sotorasib 960 mg daily | 20.8 | true | MSS | 2026-03-15T05:35:59.424410+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460708 | REC_0010296 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 7.1 | 55 | female | 0 | 10 | 6.7 | 1 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:35:59.424642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290129 | REC_0010297 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 3.1 | 66 | female | 1 | 15 | 6.1 | 5 | pembrolizumab 200 mg q3w | 8.3 | false | MSS | 2026-03-15T05:35:59.424932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800210 | REC_0010298 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 18.6 | 65 | male | 0 | 15 | 4.3 | 2 | osimertinib 80 mg daily | 26.5 | true | MSI-H | 2026-03-15T05:35:59.425174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720995 | REC_0010299 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 8 | 66 | female | 1 | 37 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.2 | true | MSS | 2026-03-15T05:35:59.425413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504630 | REC_0010300 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 3.4 | 66 | female | 0 | 50 | 4.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.6 | false | MSS | 2026-03-15T05:35:59.425646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.